{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T10:06:46Z","timestamp":1779012406807,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100013018","name":"Hospital for Special Surgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR072583"],"award-info":[{"award-number":["P30 AR072583"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Glucocorticoids are commonly used for rheumatoid arthritis (RA) treatment and to palliate some malignancies, but it is unclear whether glucocorticoids attenuate the benefits of immune checkpoint inhibitor (ICI) cancer therapy. We examined the association between glucocorticoid use and survival among ICI\u2010treated patients with RA and metastatic nonsmall cell lung cancer (mNSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of patients with RA enrolled in Medicare were identified based on the following: age \u226566 years, RA diagnosed before mNSCLC, and having initiated nivolumab, pembrolizumab, or atezolizumab (2015\u20132019, when approved only for mNSCLC). Landmark Kaplan\u2010Meier curves and time\u2010varying adjusted Cox models were used to examine the association between early glucocorticoid use (within 91 days after ICI initiation) and survival. Dexamethasone users were excluded from the primary analysis and included in a sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 663 ICI\u2010treated patients with RA and mNSCLC, with a mean age of 75 years, 86.9% being White, 64.7% being female, and 363 (46%) receiving glucocorticoids. Among users, the median average prednisone equivalents was 6.59 mg\/d (interquartile range 3.30, 12.31). In a time\u2010varying Cox model, glucocorticoid use was not associated with survival. Additionally, in a 91\u2010day landmark model, glucocorticoid dose was not associated with survival (hazard ratio 1.01; 95% confidence interval 0.93, 1.10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Glucocorticoids, at the dosages used to treat ICI\u2010treated patients with RA and mNSCLC, had a negligible effect on survival in the 91 days after ICI initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43445","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T10:05:09Z","timestamp":1764065109000},"page":"1038-1044","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-379X","authenticated-orcid":false,"given":"Deanna","family":"Jannat\u2010Khah","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology Hospital for Special Surgery  New York New York"},{"name":"Department of Medicine, Division of Rheumatology Weill Cornell Medicine  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham"},{"name":"Foundation for Advancing Science Technology, Education and Research  Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglong","family":"Xie","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science Technology, Education and Research  Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology Weill Cornell Medicine  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-8351","authenticated-orcid":false,"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology Hospital for Special Surgery  New York New York"},{"name":"Department of Medicine, Division of Rheumatology Weill Cornell Medicine  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.02.002"},{"key":"e_1_2_6_3_1","unstructured":"Cancer Stat Facts: Lung and Bronchus Cancer.SEER. Accessed October 20 2022.https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2238"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2868"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152335"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219872786"},{"key":"e_1_2_6_8_1","unstructured":"FDA approves nivolumab plus ipilimumab for first\u2010line mNSCLC (PD\u2010L1 tumor expression \u22651%).FDA. Published May 15 2020. Accessed July 3 2024.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010nivolumab\u2010plus\u2010ipilimumab\u2010first\u2010line\u2010mnsclc\u2010pd\u2010l1\u2010tumor\u2010expression\u20101"},{"key":"e_1_2_6_9_1","unstructured":"FDA approves nivolumab plus ipilimumab and chemotherapy for first\u2010line treatment of metastatic NSCLC.FDA. Updated May 27 2020. Accessed July 3 2024.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010nivolumab\u2010plus\u2010ipilimumab\u2010and\u2010chemotherapy\u2010first\u2010line\u2010treatment\u2010metastatic\u2010nsclc"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.075"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-635"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14182"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.012"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00380-1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00191"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00064-4"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000457"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25561"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31491-5"},{"key":"e_1_2_6_25_1","unstructured":"SEER\u2010Medicare: Brief Description of the SEER\u2010Medicare Database.National Cancer Institute. Updated May 16 2019. Accessed July 3 2024.https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3953"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.43445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:23:06Z","timestamp":1779009786000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/art.43445"],"URL":"https:\/\/doi.org\/10.1002\/art.43445","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"2025-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}